The aml Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the aml Hub cannot guarantee the accuracy of translated content. The aml and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The AML Hub is an independent medical education platform, sponsored by Astellas, Daiichi Sankyo, Johnson & Johnson, Kura Oncology and Syndax, and has been supported through educational grants from Bristol Myers Squibb and the Hippocrate Conference Institute, an association of the Servier Group. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View aml content recommended for you
Phase I trial demonstrates the safety of annamycin in patients with AML
A phase I open-label, single-arm US trial demonstrated the safety of annamycin in patients with relapsed/refractory (R/R) acute myeloid leukemia (AML).1
Annamycin is a next-generation, liposome-formulated anthracycline that, in 2019, received FDA Fast Track designation for the treatment of patients with R/R AML. Annamycin has been designed to avoid the cardiotoxicity and multidrug resistance that often occur with approved anthracyclines.
In this phase I trial, annamycin was given to patients at or below the FDA-established maximum dose for anthracycline, and the cardiotoxicity was determined by echocardiograms and cardiac health biomarkers, such as blood troponin levels. The study met its primary safety endpoint, with no evidence of cardiotoxicity. No unexpected serious adverse events or dose-limiting toxicities were observed in any of the six patients evaluated in this trial.
In addition, a preliminary efficacy assessment showed that one out of six patients achieved CR with incomplete recovery of platelets or neutrophils, and another patient had a substantial remission of leukemia cutis, from diffuse to 3 small lesions.
Further studies may provide evidence for annamycin efficacy in patients with R/R AML while avoiding cardiotoxicity associated with the currently approved anthracyclines.
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content